CSVAC (a circumsporozoite protein vaccine against malaria using the adenovirus Ch63 and MVA vectors (EMVI call 2007)

Inventor:  Prof. Adrian Hill, University of Oxford
Project Team Leader:  Babatunde Imoukhuede, EVI
Product Leader:  to be selected
Manufacturer:  to be selected
Clinical Trial Principal Investigator:  Prof. Samuel J. McConkey, Royal College of Surgeons in Ireland

Product Development
A contract has been signed with the University of Oxford for the construction and GMP manufacturer of AdCh63 and MVA CSP.

Clinical Development
The contract stated under Product Development also covers Phase I clinical trials of AdCh63 and MVA CSP.

The contract, which has a budget of €1 261 000, will last for 30 months.